Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Amondys 45 Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0137

    Amondys 45

    Customize your policy alerts

    Sign up for Cigna Policy IP0137 alerts

    Get alerted when Policy IP0137 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity for Amondys 45 (casimersen intravenous infusion) for patients with Duchenne muscular dystrophy. It applies to providers requesting prescription benefit coverage and requires specified clinical documentation, specialist involvement, and dosing.

    Policy Summary
    PayerCigna
    PolicyAmondys 45
    Policy CodePolicy IP0137
    Change TypeMaterial revision
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation confirming the applicable clinical criteria and dosing requirements.
    SourceLink
    POLICY UPDATE CHANGES

    Initial-therapy criteria now require that the patient has not received Elevidys.

    The walking requirement was revised from a minimum independent 6-minute walk distance to ability to walk with submission of baseline 6-minute walk test results.

    The forced vital capacity requirement was removed from the initial-therapy criteria.

    Continuation therapy criteria were revised to require confirmation of an exon-45-skipping-amenable DMD mutation, age younger than 14 years at therapy initiation, and current ability to walk.

    Concurrent use with other exon-skipping DMD therapies is explicitly identified as not medically necessary.

    6 monthsApproval duration
    30 mg/kg weeklyDose
    35–60 min

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Infusion duration
    <14 yearsAge at start
    Exon 45Mutation
    J1426Covered HCPCS

    Medical Necessity and Coverage Criteria

    FDA-Approved Indication: Duchenne Muscular Dystrophy

    Covered when the patient meets ONE of the following Duchenne muscular dystrophy pathways:

    ONE of

    • Initial Therapy

      • Age: Patient is younger than 14 years of age at the start of therapy.<14 years
      • Genetic confirmation: Diagnosis of Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene that is amenable to exon 45 skipping.

        Documentation required.

      • Ambulation and baseline testing: Patient is able to walk and baseline 6-minute walk test (6MWT) results are submitted.

        Documentation required.

      • Elevidys history: Patient has not received Elevidys.No prior Elevidys
      • Prescriber expertise: Medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.
    • Currently Receiving Amondys 45

      • Genetic confirmation: Diagnosis of Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene that is amenable to exon 45 skipping.

        Documentation required.

      • Age at therapy initiation: Patient was younger than 14 years of age at the start of therapy.<14 years at start
      • Ambulation: Patient is able to walk.Ambulatory

        Documentation required.

      • Prescriber expertise: Medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.

    Concurrent use with other exon-skipping Duchenne muscular dystrophy (DMD) agents is considered not medically necessary. Examples include Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

    Amondys 45 is considered not medically necessary for uses outside the covered FDA-approved indication for Duchenne muscular dystrophy, including concurrent use with other exon-skipping DMD agents.

    Medically Necessary Coding

    Medically Necessary HCPCS CodeHCPCSCovered
    J1426Injection, casimersen, 10 mg

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for prescription benefit coverage of Amondys 45. Requests for doses outside the established dosing may be reviewed case by case by a Medical Director or Pharmacist.

    Documentation Required

    Specialist Involvement Required

    Amondys 45 must be prescribed by or in consultation with a physician who specializes in the condition being treated.

    • Acceptable specialists include a neurologist, neuromuscular specialist, or Muscular Dystrophy Association (MDA) care center or clinic.
    Documentation Required

    Clinical and Genetic Documentation

    Therapy Background

    Amondys 45 (casimersen) is an antisense oligonucleotide indicated for Duchenne muscular dystrophy in patients with a confirmed pathogenic or likely pathogenic DMD gene variant amenable to exon 45 skipping. The indication received accelerated approval based on increased dystrophin in skeletal muscle, with continued approval potentially contingent on confirmation of clinical benefit.

    Key Clinical Definitions

    Amenable to exon 45 skipping
    DefinitionA DMD gene mutation for which casimersen-mediated exon 45 skipping is applicable.
    6-minute walk test (6MWT)
    DefinitionA baseline assessment of walking ability performed over six minutes and required for initial therapy documentation.

    Initial Therapy

    Initial Therapy

    Approve for 6 months when ALL of the following initial-therapy criteria are met:

    ALL of the following

    • Age: Patient is younger than 14 years of age at the start of therapy.<14 years
    • Genetic confirmation: Diagnosis of Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene that is amenable to exon 45 skipping.

      Documentation required.

    • Ambulation and baseline testing: Patient is able to walk and baseline 6-minute walk test (6MWT) results are submitted.Baseline 6MWT results

    Continuation Therapy

    Currently Receiving Amondys 45

    Approve for 6 months when ALL of the following continuation criteria are met:

    ALL of the following

    • Genetic confirmation: Diagnosis of Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene that is amenable to exon 45 skipping.

      Documentation required.

    • Age at start: Patient was younger than 14 years of age at the start of therapy.<14 years at start
    • Ambulation: Patient is able to walk.Ambulatory

    Dose and Frequency

    Amondys 45 (casimersen)
    Recommended dose30 mg/kg administered once weekly.

    Administration Requirements

    Note

    Administer in the infusion center

    Administer Amondys 45 as a 35- to 60-minute intravenous infusion.

    Policy Summary
    PayerCigna
    PolicyAmondys 45
    Policy CodePolicy IP0137
    Change TypeMaterial revision
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation confirming the applicable clinical criteria and dosing requirements.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaMedically Necessary CodingAuthorization, Documentation, and Denial RisksTherapy BackgroundKey Clinical DefinitionsInitial TherapyContinuation TherapyDose and FrequencyAdministration Requirements

    Submit patient-specific clinical and genetic documentation when required by the applicable criteria. Documentation must support the Duchenne muscular dystrophy diagnosis, an amenable pathogenic or likely pathogenic DMD-gene variant, and applicable therapy criteria.

    • Initial therapy: document the qualifying DMD gene variant and baseline six-minute walk test (6MWT) results.
    • Continuation therapy: document the qualifying DMD gene variant and that the patient is able to walk.
    Documentation Required

    Submit Supporting Records

    Supporting records are required where noted and must include patient-specific identifying information.

    • Chart notes
    • Laboratory tests
    • Medical test results
    • Claims records
    • Prescription receipts
    • Other relevant supporting information
    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when applicable initial-therapy or continuation-therapy criteria are not met, including age, genetic, ambulatory, prior-treatment, specialist, or documentation requirements.

    • Initial therapy requires the patient to be under age 14 at the start of therapy, have an amenable DMD-gene variant, be able to walk with baseline 6MWT results submitted, and not have received Elevidys.
    • Continuation therapy requires the patient to have been under age 14 at the start of therapy, have an amenable DMD-gene variant, and be able to walk.
    Denial Risk

    Concurrent Exon-Skipping Therapy

    Concurrent use of Amondys 45 with another exon-skipping Duchenne muscular dystrophy agent is not medically necessary because clinical evidence does not support concurrent use.

    • Examples include Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).
    Billing Rule

    Incorrect Diagnosis or Billing Code

    Claims may be denied when submitted for a diagnosis or service that is not covered under the policy or without the applicable covered code(s). Use the most appropriate codes effective on the submission date.

    • Covered HCPCS code: J1426 — Injection, casimersen, 10 mg.
    • Deleted codes or codes not effective on the date of service may not be eligible for reimbursement.
    • The code list may not be all-inclusive; billing the covered code does not replace the applicable clinical criteria.

    Documentation required.

  1. Elevidys history: Patient has not received Elevidys.No prior Elevidys
  2. Specialist prescribing: Medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.
  3. Documentation required.

  4. Specialist oversight: Medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.